BioNTech Acquires Chinese Oncology Firm Biotheus for $950M

The Care and Protection of Children Trust

CPCT Launches Groundbreaking Initiative to Provide Lifelong Free Treatment for Children with Spinal Muscular Atrophy (SMA) in Karnataka

Early Comprehensive Genomic Profiling Improves Cancer Treatment Outcomes, Study Shows

EMA Reverses Decision, Recommends Limited Approval for Eisai and Biogen’s Alzheimer’s Drug Leqembi

Exact Sciences Unveils Advances in Multi-Cancer Early Detection with Cancerguard™ Test

MSD and LaNova Medicines Enter Exclusive Global License Agreement for Novel Cancer Therapy, LM-299

Promising CAR T Cell Therapies from BMS and Cabaletta Bio Show Potential for Durable Remission in Severe Lupus

FDA Grants Accelerated Approval to PTC Therapeutics' KEBILIDI™, the First Gene Therapy for AADC Deficiency in the U.S.

Association for Molecular Pathology Publishes Joint Consensus Report on SARS-CoV-2 Genomic Surveillance for Hospitals and Public Health Laboratories

Philips India Unveils Advanced Azurion Imaging System to Revolutionize Cardiac and Neurovascular Care

Tempus AI Study Highlights Benefits of Dual RNA and DNA Sequencing for Advanced Lung Cancer

Ontada and Datavant Partner to Expand Access to Real-World Oncology Data for Accelerated Cancer Innovation

Tempus AI and Flatiron Health Partner to Integrate Genomic Testing into OncoEMR for Enhanced Oncology Care

Flare Therapeutics and Roche Forge Strategic Partnership to Discover Precision Oncology Therapies Targeting Transcription Factors

FDA Approves Autolus’s CAR-T Therapy Aucatzyl for Relapsed or Refractory B-ALL in Adults

Home
/
update
/
details

Sysmex Expands Strategic Alliance with QIAGEN to Advance Genetic Testing Collaboration

NextEdge Admin

08 Aug 2024

1 min 51 sec

Sysmex Corporation has expanded its strategic alliance with QIAGEN N.V. to enhance their collaboration in genetic testing, covering research and development, production, clinical development, and sales-marketing.

Since their initial partnership in 2013 and the strategic alliance for companion diagnostics in 2021, Sysmex and QIAGEN have successfully collaborated. The expanded alliance will leverage their respective strengths in genetic testing to deliver high-value products globally. Sysmex will utilize QIAGEN’s assays for clinical trials conducted by pharmaceutical companies and research institutions at Sysmex's global network laboratories, including Sysmex Inostics, Inc. CLIA lab, Sysmex Research and Development Center, and RIKEN GENESIS Co., Ltd.

For over 50 years, Sysmex has advanced its global presence in in vitro diagnostics, focusing on personalized medicine and liquid biopsy technology. With world-class laboratories in Japan and the U.S., Sysmex aims to accelerate high-value testing and diagnostic technology development.

QIAGEN, a pioneer in precision medicine, collaborates with pharmaceutical and biotech companies to develop companion diagnostics that detect genetic abnormalities, aiding clinical decision-making. Offering technologies from PCR to next-generation sequencing (NGS), QIAGEN tailors products to pharmaceutical needs, with collaboration agreements with over 30 global pharma companies.